Printer Friendly

Nymox AlzheimAlert Used by Legal Experts in Forensic Cases.

Business/Health Editors

MAYWOOD, N.J.--(BW HealthWire)--July 10, 2001

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) AlzheimAlert(TM) is a tool increasingly used by forensic experts in order to address some of the complex legal issues surrounding the diagnosis of Alzheimer's disease. AlzheimAlert(TM) tests have been ordered by parties in both civil and criminal proceedings in order to assist in determining a diagnosis of Alzheimer's disease.

The need for an accurate diagnosis of Alzheimer's disease arises in a wide range of important legal contexts. In criminal proceedings, the finding that a defendant suffers from Alzheimer's disease may be relevant to an insanity defense or to competency to stand trial. Other issues include whether a witness is competent to testify or is otherwise believable because of the effects of Alzheimer's disease. In the civil arena, questions concerning the reliability of the diagnosis of Alzheimer's disease arise when the capacity of a person to make informed medical decisions, to manage his or her affairs, or to change a will becomes an issue.

As the baby boom generation ages, these types of issues surrounding the diagnosis of Alzheimer's disease can be expected to occur more frequently.

There is a strong consensus among healthcare experts about the need for the early accurate diagnosis of Alzheimer's disease for treatment and care. The importance of early diagnosis has been identified for example by the Surgeon General in his Report on Mental Health and more recently by the American Medical Association in its media briefing on Alzheimer's disease.

Nymox offers its AlzheimAlert(TM) test as an aid to physicians in the diagnosis of Alzheimer's disease. The test is a state-of -the-art urine test that detects a brain protein called neural thread protein (NTP) that is known to be elevated in patients with Alzheimer's disease. AlzheimAlert(TM) is available to physicians through its certified Clinical Reference Laboratory in Maywood, New Jersey at a cost of $295.

There is an extensive scientific literature over the past decade linking NTP to Alzheimer's disease and confirming its accuracy as a biochemical marker for this devastating illness. Recent publications in the peer-reviewed literature include the Journal of Clinical Investigation (1997; 100: 3093-3104); Journal of Contemporary Neurology (1998; art. 4a); Journal of Clinical Laboratory Analysis (1998; 12: 285-288) and (1998; 12: 223-226); Alzheimer's Reports (1999; 2: 327-332), (2000; 3: 177-184) and (2001; vol.4, no.2); Neurology (2000; 54: 1498-1504) and (2000; 55: 1068); Journal of Neuropathology and Experimental Neurology (2001; 60: 195-207); and Journal of Alzheimer's Disease (2001; 3: 345-353).

Nymox also has two principal programs to develop treatments for Alzheimer's disease, both based on proprietary drug screening platforms. The first program targets NTP and its role in the extensive brain cell loss associated with Alzheimer's disease. The second program is based on spherons. Spherons are tiny dense balls of protein found in the brains of everyone from age one. Nymox researchers believe that spherons are the source of senile plaques, the characteristic abnormality found in abundance in the brains of patients with Alzheimer's disease and widely believed to play a major role in the cause and course of the illness. Nymox researchers believe that stopping or inhibiting the transformation of spherons into senile plaques will stop or slow the progress of this devastating illness. They have succeeded in extracting spherons from human brain tissue and developing novel, proprietary drug screening methodologies based on them.

Nymox also has several antibacterials in development, including potential treatments for E. coli 0157 food contamination, and other antibacterials for urinary tract infections and staph and strep infections. The Company's R&D pharmaceutical pipeline also includes candidate drugs for other indications in development. Nymox's second proprietary marketed product, NicAlert(TM), is available in the U.S. and Japan. NicAlert(TM) is an inexpensive, simple-to-use test strip that uses urine or saliva to determine whether a person is using tobacco products. It is currently being used in studies of tobacco use and exposure across the U.S., and as a test to determine whether a person, such as a teenager, student athlete or insurance applicant, is using a tobacco product. Nymox Pharmaceutical Corporation has facilities in Maywood, NJ and Montreal. Its stock is traded on NASDAQ with the symbol NYMX. More information is available at http://www.nymox.com.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
COPYRIGHT 2001 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jul 10, 2001
Words:790
Previous Article:General Semiconductor Receives Award From the Bosch Group; Company Recognized for its Outstanding Performance as a Supplier.
Next Article:Arbitron Inc. Second Quarter Earnings Release and Conference Call Scheduled for July 19, 2001.
Topics:


Related Articles
Nymox's AlzheimAlert Test Featured in Current Issue of Lab Magazine.
Nymox Reports Successful AlzheimAlert Clinical Study Published In Neurology & Clinical Neurophysiology.
Nymox Pharmaceutical Corp. to Hold Third Manhattan Alzheimer Disease Conference in November 2001.
Nymox Pharmaceutical Corp. to Hold Third Manhattan Alzheimer Disease Conference in November 2001.
Nymox AlzheimAlert Urine Test Shows Promise to Monitor Alzheimer Treatment and Progression According to New Study.
Online Publication of Successful Clinical Study of Nymox's AlzheimAlert Test.
Nymox Presents Positive AlzheimAlert Results at Annual Meeting of American Geriatrics Society.
Fourth Manhattan Alzheimer's Disease Conference on May 27 Sponsored by Nymox Will Feature World Class Assembly of Speakers and Panelists.
Nymox Products Widely Featured on U.S. Television.
Nymox Reports New Positive Studies of AlzheimAlert Product.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters